Botulinum toxin for masseter hypertrophy

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Fedorowicz, Zbys ^a   van Zuuren, Esther J ^b   Schoones, Jan ^b  

^a Bahrain Branch   (Bahrain)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; MASSETER MUSCLE; MUSCLE HYPERTROPHY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; HYPERTROPHY; INTRAMUSCULAR DRUG ADMINISTRATION; PATHOLOGY;

BOTULINUM TOXINS, TYPE A; HUMANS; HYPERTROPHY; INJECTIONS, INTRAMUSCULAR; MASSETER MUSCLE; NEUROMUSCULAR AGENTS;

EID: 84898753114     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007510.pub3     Document Type: Review

References (40)

1. Ahn KY, Kim ST. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. Plastic and Reconstructive Surgery 2007;120(6):1662-6.
2. Bhogal PS, Hutton A, Monaghan A. A review of the current uses of Botox for dentally-related procedures. Dental Update 2006;33(3):165-8.
3. Castro WH, Gomez RS, Da Silva Oliveira J, Moura MD, Gomez RS. Botulinum toxin type A in the management of masseter muscle hypertrophy. Journal of Oral and Maxillofacial Surgery 2005;63(1):20-4.
4. Chikhani L, Dichamp J. Bruxism, temporo-mandibular dysfunction and botulinum toxin. Annales de Réadaptation et de Médecine Physique 2003;46(6):333-7.
5. Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatologic Surgery 2005;31(5):502-7.
6. Collier J, Zou L. Quantitative measurement of the response of masseteric hypertrophy to treatment with botulinum toxin type-A. British Journal of Oral and Maxillofacial Surgery 2009;47(7):e30.
7. Hui AC. Botulinum toxin for treatment of masseteric hypertrophy. Journal of Neurology 2002;249(3):345.
8. Işeri M, Işeri PK. Treatment of unilateral masseter hypertrophy with botulinum toxin in two cases. Kulak Burun Boğaz Ihtisas Dergisi 2004;12(3-4):99-102.
9. Jin SP, Cho S, Youn C, Feneran A, Haw S, Bak H, et al.Effectiveness of botulinum toxin type A and B in benign masseteric hypertrophy. Journal of Dermatology 2010;37(Suppl 1):78.
10. Kane MA. Botulinum toxin A for lower facial contouring: A prospective study. Aesthetic Plastic Surgery 2007;31(5):452-3.
11. Kaynar A, Parman Y, Poyanl A, Demirkol O, Birinci SH, Minareci O, et al.Therapeutic use of botulinum toxin in the treatment of masseter hypertrophy. International Journal of Oral and Maxillofacial Surgery 1997;26(Suppl 1):116.
12. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatologic Surgery 2003;29(5):484-9.
13. Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI. Electrophysiologic change and facial contour following botulinum toxin A. Plastic and Reconstructive Surgery 2007;120(3):769-78.
14. Mischkowski RA, Siessegger M, Lazar F, Zöller JE. Chemodenervation with botulinum toxin in masseteric hypertrophy. Mund-, Kiefer-und Gesichtschirurgie 2005;9(2):101-8.
15. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. British Journal of Oral and Maxillofacial Surgery 1994;32(1):26-8.
16. Niamtu J. Aesthetic uses of botulinum toxin A. Journal of Oral and Maxillofacial Surgery 1999;57(10):1228-33.
17. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatologic Surgery 2003;29(5):477-83.
18. Rogers BA, Whear NM. Medical management of masseteric hypertrophy. Journal of Oral and Maxillofacial Surgery 1995;53(4):492.
19. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. British Journal of Oral and Maxillofacial Surgery 1994;32(1):29-33.
20. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, et al.A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. British Journal of Plastic Surgery 2001;54(3):197-200.
21. von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plastic and Reconstructive Surgery 2001;107(2):327-32.
22. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. Journal of Oral and Maxillofacial Surgery 2003;61(7):774-8.
23. Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plastic Surgery 2007;31(5):445-51.
24. Giudice M, Marra A, Barba A, Passariello N, D'Onofrio F. Hypertrophy of the masseter: a rare case associated with hypertrophic cardiomyopathy. Minerva Stomatologica 1992;41(11):535-42.
25. Harriman DG. The histochemistry of reactive masticatory muscle hypertrophy. Muscle and Nerve 1996;19:1447-56.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Jin Park Y, Woo Jo Y, Bang SI, Kim HJ, Lim SY, Mun GH, et al.Radiofrequency volumetric reduction for masseteric hypertrophy. Aesthetic Plastic Surgery 2007;31(1):42-52.
28. Kim HJ, Jeon BS, Lee KW. Hemimasticatory spasm associated with localized scleroderma and facial hemiatrophy. Archives of Neurology 2000;57(4):576-80.
29. Kitagawa Y, Hashimoto K, Kuriyama M. Hypertrophic branchial myopathy with uniform predominance of type 1 fibres. Case report. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery 2000;34(4):391-6.
30. Legg JW. Enlargement of the temporal and masseter muscles on both sides. Transactions of the Pathological Society of London 1880;31:361-6.
31. Newton JP, Cowpe JG, McClure IJ, Delday MI, Maltin CA. Masseteric hypertrophy?: preliminary report. British Journal of Oral and Maxillofacial Surgery 1999;37(5):405-8.
32. Nishida M, Iizuka T. Intraoral removal of the enlarged mandibular angle associated with masseteric hypertrophy. Journal of Oral Maxillofacial Surgery 1995;53(12):1476-9.
33. Papapetropoulos S, Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head and Face Medicine 2006;7(2):47.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
35. Sannomya EK, Gonçalves M, Cavalcanti MP. Masseter muscle hypertrophy: case report. Brazilian Dental Journal 2006;17(4):347-50.
36. Satoh K, Yamaguchi T, Komatsu K, Inoue N, Minowa K, Kanayama T, et al.Analyses of muscular activity, energy metabolism, and muscle fiber type composition in a patient with bilateral masseteric hypertrophy. Cranio 2001;19(4):294-301.
37. Serrat A, Garcia-Cantera JM, Redondo LM. Isolated unilateral temporalis muscle hypertrophy. A case report. International Journal of Oral Maxillofacial Surgery 1998;27(2):92-3.
38. Skoura C, Mourouzis C, Saranteas T, Chatzigianni E, Tesseromatis C. Masseteric hypertrophy associated with administration of anabolic steroids and unilateral mastication: a case report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 2001;92(5):515-8.
39. Wilson PS, Brown AM. Unilateral temporalis muscle hypertrophy: Case report. International Journal of Oral Maxillofacial Surgery 1990;19(5):287-8.
40. Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, Al Bareeq R, Nasser M. Botulinum toxin for masseter hypertrophy. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007510.pub2]